Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "2020"

617 News Found

NPPA issues notice to manufacturers and importers of knee implants
Policy | August 05, 2021

NPPA issues notice to manufacturers and importers of knee implants

The data should be submitted by August 12th 2021


IPCA Labs  reports Q1FY22 net at Rs 306.66 Cr
News | August 05, 2021

IPCA Labs reports Q1FY22 net at Rs 306.66 Cr

Total income grew in the quarter


Caplin Point Laboratories posts consolidated PAT in Q1FY22 at Rs 70.85 Cr
News | August 05, 2021

Caplin Point Laboratories posts consolidated PAT in Q1FY22 at Rs 70.85 Cr

EPS climbs to Rs 9.25 for the quarter


Combinations of Sputnik V component with other vaccines demonstrate favourable results: RDIF
Drug Approval | August 05, 2021

Combinations of Sputnik V component with other vaccines demonstrate favourable results: RDIF

AstraZeneca, Sinopharm and Moderna were part of the study


Govt committed to recognise healthcare workers engaged in Covid-19
Policy | August 04, 2021

Govt committed to recognise healthcare workers engaged in Covid-19

Five seats reserved for Wards of COVID warriors in central MBBS admission


Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22
News | August 04, 2021

Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22

Aditya Puri former MD of HDFC bank joins Solara board as chairman


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.


Drug exports grow on the back of govt support
Policy | August 03, 2021

Drug exports grow on the back of govt support

Drug formulations and biologics make impressive gains


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials